These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 31073686)
21. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs). Riley T; Christopher D; Arp J; Casazza A; Colombani A; Cooper A; Dey M; Maas J; Mitchell J; Reiners M; Sigari N; Tougas T; Lyapustina S AAPS PharmSciTech; 2012 Sep; 13(3):978-89. PubMed ID: 22798037 [TBL] [Abstract][Full Text] [Related]
22. Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs. Malmlöf M; Nowenwik M; Meelich K; Rådberg I; Selg E; Burns J; Mascher H; Gerde P Eur J Pharm Biopharm; 2019 Jun; 139():213-223. PubMed ID: 30862480 [TBL] [Abstract][Full Text] [Related]
23. What makes flunisolide different among inhaled corticosteroids used for nebulization: a close look at the role of aqueous solubility. Kantar A Multidiscip Respir Med; 2021 Jan; 16(1):719. PubMed ID: 33489120 [TBL] [Abstract][Full Text] [Related]
24. Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products. Velaga SP; Djuris J; Cvijic S; Rozou S; Russo P; Colombo G; Rossi A Eur J Pharm Sci; 2018 Feb; 113():18-28. PubMed ID: 28887232 [TBL] [Abstract][Full Text] [Related]
25. A Multi-laboratory in Vitro Study to Compare Data from Abbreviated and Pharmacopeial Impactor Measurements for Orally Inhaled Products: a Report of the European Aerosol Group (EPAG). Nichols SC; Mitchell JP; Sandell D; Andersson PU; Fischer M; Howald M; Pengilley R; Krüger P AAPS PharmSciTech; 2016 Dec; 17(6):1383-1392. PubMed ID: 26762338 [TBL] [Abstract][Full Text] [Related]
26. Fluticasone Particles Bind to Motile Respiratory Cilia: A Mechanism for Enhanced Lung and Systemic Exposure? Lee DDH; Cardinale D; Terakosolphan W; Sornsute A; Radhakrishnan P; Coppel J; Smith CM; Satyanarayana S; Forbes B; O'Callaghan C J Aerosol Med Pulm Drug Deliv; 2021 Jun; 34(3):181-188. PubMed ID: 32960118 [No Abstract] [Full Text] [Related]
27. Characterization of Membrane-Type Dissolution Profiles of Clinically Available Orally Inhaled Products Using a Weibull Fit and a Mechanistic Model. van der Zwaan I; Franek F; Fransson R; Tehler U; Frenning G Mol Pharm; 2022 Sep; 19(9):3114-3124. PubMed ID: 35939615 [TBL] [Abstract][Full Text] [Related]
29. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate. Kaliner MA Clin Ther; 2006 Mar; 28(3):319-31. PubMed ID: 16750447 [TBL] [Abstract][Full Text] [Related]
30. Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA. Park HS; Yoon D; Lee HY; Ban GY; Wan Yau Ming S; Jie JLZ; Carter V; Hardjojo A; Van Boven JFM; Price DB Respirology; 2019 Oct; 24(10):972-979. PubMed ID: 31038269 [TBL] [Abstract][Full Text] [Related]
31. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Casale TB; Nelson HS; Stricker WE; Raff H; Newman KB Ann Allergy Asthma Immunol; 2001 Nov; 87(5):379-85. PubMed ID: 11730179 [TBL] [Abstract][Full Text] [Related]
32. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations. Hein S; Bur M; Schaefer UF; Lehr CM Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200 [TBL] [Abstract][Full Text] [Related]
33. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin. Pai RV; Jain RR; Bannalikar AS; Menon MD J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162 [TBL] [Abstract][Full Text] [Related]
34. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device. Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675 [TBL] [Abstract][Full Text] [Related]
35. Inhaled corticosteroid metered-dose inhalers: how do variations in technique for solutions versus suspensions affect drug distribution? Robinson CA; Tsourounis C Ann Pharmacother; 2013 Mar; 47(3):416-20. PubMed ID: 23482731 [TBL] [Abstract][Full Text] [Related]
36. [Development of a spacer for inhaled corticosteroid. Evaluation using flunisolide metered dose aerosol]. Schmelzer C; Weber E; Köhler ME Fortschr Med; 1991 Jan; 109(1):43-6. PubMed ID: 2022352 [TBL] [Abstract][Full Text] [Related]
37. Quantification of Aerosol Hydrofluoroalkane HFA-134a Elimination in the Exhaled Human Breath Following Inhaled Corticosteroids Administration. Shin HW; Barletta B; Yoonessi L; Meinardi S; Leu SY; Radom-Aizik S; Randhawa I; Nussbaum E; Blake DR; Cooper DM Clin Transl Sci; 2015 Oct; 8(5):445-50. PubMed ID: 26155923 [TBL] [Abstract][Full Text] [Related]
38. Dissolution techniques for in vitro testing of dry powders for inhalation. May S; Jensen B; Wolkenhauer M; Schneider M; Lehr CM Pharm Res; 2012 Aug; 29(8):2157-66. PubMed ID: 22528980 [TBL] [Abstract][Full Text] [Related]